Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States

BACKGROUND: The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite expensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Dempsey, Timothy M., Thao, Viengneesee, Moriarty, James P., Borah, Bijan J., Limper, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744245/
https://www.ncbi.nlm.nih.gov/pubmed/35000589
http://dx.doi.org/10.1186/s12890-021-01811-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744245/
https://www.ncbi.nlm.nih.gov/pubmed/35000589
http://dx.doi.org/10.1186/s12890-021-01811-0

Ejemplares similares